EyePoint Pharmaceuticals, Inc.
EYPT
$5.55
-$0.12-2.12%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -17.39% | -30.77% | 4.09% | 52.08% | 33.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -17.39% | -30.77% | 4.09% | 52.08% | 33.18% |
| Cost of Revenue | -70.42% | 60.41% | 86.01% | 116.71% | -305.16% |
| Gross Profit | 47.70% | -511.62% | -30.34% | -192.23% | 698.63% |
| SG&A Expenses | 16.04% | 23.25% | -9.00% | -5.82% | -14.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 87.04% | 46.19% | 38.15% | 53.93% | -9.49% |
| Operating Income | -176.62% | -127.45% | -51.78% | -54.59% | 29.01% |
| Income Before Tax | -194.73% | -132.80% | -34.49% | -38.37% | 67.74% |
| Income Tax Expenses | 8.43% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -193.63% | -132.80% | -34.49% | -38.37% | 67.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -193.63% | -132.80% | -34.49% | -38.37% | 67.55% |
| EBIT | -176.62% | -127.45% | -51.78% | -54.59% | 29.01% |
| EBITDA | -175.66% | -126.42% | -51.06% | -53.94% | 28.45% |
| EPS Basic | -91.78% | -63.94% | 5.02% | 1.98% | 71.25% |
| Normalized Basic EPS | -92.54% | -63.91% | -0.92% | 1.98% | 45.44% |
| EPS Diluted | -91.78% | -63.94% | 5.02% | 1.98% | 71.25% |
| Normalized Diluted EPS | -92.54% | -63.91% | -0.92% | 1.98% | 45.44% |
| Average Basic Shares Outstanding | 53.09% | 42.01% | 41.60% | 41.15% | 12.89% |
| Average Diluted Shares Outstanding | 53.09% | 42.01% | 41.60% | 41.15% | 12.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |